BioCentury
ARTICLE | Clinical News

ESN364: Completed Phase IIa enrollment

September 19, 2016 7:00 AM UTC

Euroscreen completed enrollment of 87 patients in a double-blind, placebo-controlled, Belgian Phase IIa trial evaluating 90 mg oral ESN364 for 12 weeks. ...